• Product NameATF2(Phospho-Thr71 or 53) Antibody
• Host SpeciesRabbit
• ClonalityPolyclonal
• PurificationAntibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
• ApplicationsWB IHC
• Species ReactivityHu Ms Rt
• SpecificityThe antibody detects endogenous level of ATF-2 only when phosphorylated at threonine 71 or 53.
• Immunogen TypePeptide-KLH
• Immunogen DescriptionPeptide sequence around phosphorylation site of threonine 71 or 53 (T-P-T(p)-P-T) derived from Human ATF2.
• Target NameATF2
• ModificationPhospho
• Alternative Names    CREB2; CREBP1;
• Accession No. Swiss-Prot: P15336
  NCBI Protein: NP_001871.2
• UniprotP15336
• Gene ID1386;
• Concentration 1.0mg/ml
• Formulation Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Storage Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.

• Predicted MW: 65-75 kd
  Western blotting: 1:500~1:1000
  Immunohistochemistry: 1:50~1:100

Transcriptional activator, probably constitutive, which binds to the cAMP-responsive element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Interaction with JUN redirects JUN to bind to CRES preferentially over the 12-O-tetradecanoylphorbol-13-acetate response elements (TRES) as part of an ATF2-c-Jun complex.

Sevilla A, et al. (2004) J Biol Chem. 279(26):27458-27465.
Waetzig G H, et al. (2002) J Immunol. 168(10): 5342-5351.
Abdel-Hafiz H A, et al. (1992) Mol Endocrinol. 6: 2079-2089.
Gupta S, et al. (1995) Science. 267: 389-393.
Van Dam H, et al. (1995) EMBO J. 14(8): 1798-1811.

• Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ATF2(Phospho-Thr71 or 53) Antibody #11031(left) or the same antibody preincubated with blocking peptide(right).
• Western blot analysis of extracts from HUVEC cells untreated or treated with Anisomycin using ATF2 (Phospho-Thr71 or 53) Antibody #11031.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting